Abstract-In comparison with essential hypertension, primary aldosteronism (PA) is associated with an increased risk of cardiovascular morbidity. To date, no data on mortality have been published. We assessed mortality of patients treated for PA within the German Conn's registry and identified risk factors for adverse outcome in a case-control study.
A ldosterone is a key regulator of fluid and electrolyte balance in human physiology. Aldosterone excess in the presence of a high-sodium diet raises blood pressure. High blood pressure, together with direct proinflammatory and profibrotic effects of aldosterone on the vessel wall, causes and sustains cardiovascular atherosclerosis. 1, 2 In keeping with these findings, high aldosterone levels are associated with mortality in heart failure cohorts, 3 and blockade of the renin-angiotensin-aldosterone system by mineralocorticoid antagonists improves outcome in heart failure and after myocardial infarction. 4, 5 The contribution of aldosterone to the development of arterial hypertension in the general population has been suggested by the Framingham Offspring Study, in which plasma aldosterone levels in normotensive subjects predicted subsequent increases in blood pressure and the development of hypertension. 6 Recent evidence suggests that primary aldosteronism (PA) is more common than previously thought. 7 Several studies have provided evidence that patients with PA are especially prone to cardiovascular and renal complications. In a recent study by Catena et al, 8 aldosterone excess caused left ventricular hypertrophy and diastolic dysfunction independent of blood pressure. Several studies have indicated a higher prevalence of cardiovascular events and stroke in PA in comparison with essential hypertension. 9, 10 Likewise, pronounced fibrosis of small resistance arteries was detected in a series of 13 patients with PA compared with blood pressurematched patients with essential hypertension. 11 Overall, these examples provide evidence that PA needs to be detected early in the course of the disease and treated appropriately. Unilateral PA is generally treated by adrenalectomy, which provokes a major fall in blood pressure in Ͼ85% of patients and blood pressure normalization in 30% to 60%. 12 A similar effect is observed in patients with idiopathic bilateral adrenal hyperplasia treated with the mineralocorticoid antagonist spironolactone. 13 Recently, a study demonstrated that either treatment reduced excess renal and cardiovascular morbidity to a level similar to that of matched essential hypertensives. 14 No study has so far investigated mortality in PA. Based on the blood pressure response to adrenalectomy or mineralocorticoid antagonist treatment, it is reasonable to assume that long-term mortality may be equal to or even lower than that of matched hypertensive controls. On the other hand, the lag period between first symptoms of PA (hypertension) and final diagnosis ranges from 9 to 12 years. 15, 16 Therefore, aldosterone excess is typically long-standing, and the proinflammatory effects of aldosterone may have led to irreversible damage to the vascular wall, the myocardium, and the kidney, increasing long-term mortality despite initiation of specific treatment. The German Conn's Registry-Else Kröner-Fresenius Hyperaldosteronism Registry was founded in 2006 and investigates disease-specific effects of PA on a broad range of outcome variables using a multicenter approach. In this study we analyzed all-cause and cardiovascular mortality in a cohort of 337 patients with PA compared with a cohort of control subjects with and without hypertension.
Methods

Description of the Registry, Study Population
The German Conn's Registry (www.conn-register.de) is a multicenter database analyzing comorbidities and long-term outcomes of patients with PA. [16] [17] [18] Since the start of the prospective phase of the registry in 2008, all patients actively treated within the centers are entered in a common database. 19 For this study, the patients of the 3 largest German centers (Berlin, nϭ55; Würzburg, nϭ102; Munich, nϭ180) treated between 1994 and 2010 were included in the analysis. The ethics committees of the University of Munich and of the participating centers approved the protocol. Data protection laws were strictly adhered to.
Clinical data at time of diagnosis were extracted from patient charts, including laboratory test results, initiation of mineralocorticoid antagonist treatment, surgical treatment, cardiovascular comorbidities, body mass index (BMI), and metabolic conditions, such as diabetes mellitus and hyperlipidemia. In case of multiple determinations, the measurements of potassium, plasma renin activity or concentration, and aldosterone at first presentation were used for statistical calculations. Blood was generally drawn in the fasting state, although this was not standardized within centers.
The diagnostic criteria for PA in this study followed those of the Endocrine Society Practice guidelines. 20 All of the patients included had an elevated aldosterone:renin ratio and an abnormal confirmatory test (acute volume loading, furosemide test, fludrocortisone suppression test, or captopril test) 16, 17 and/or had confirmation of PA by demonstration of elevated excretion of aldosterone and its metabolites in urine. Adjustment of medication before screening was performed as feasible, with ␤-blockers withdrawn for 1 week and mineralocorticoid antagonists for 4 weeks. The diagnosis of PA was centrally verified by review of all of the available data. A total of 337 patients with confirmed PA from the German Conn's Registry for whom sufficient data coverage was available were included in the final analysis. Subtype differentiation between aldosteroneproducing adenoma and bilateral adrenal hyperplasia was based on adrenal imaging (computed tomography or MRI). In addition, adrenal vein sampling was performed in 36% (Berlin), 59% (Wür-zburg), and 21% (Munich) of patients, respectively, until 2007 and in 54%, 66%, and 87%, thereafter. 21 Unilateral adrenalectomy was performed in 157 of 337 patients (47%) for suspected unilateral aldosterone excess, mainly aldosterone-producing adenoma. The remaining patients were treated with mineralocorticoid receptor antagonists.
In 2009 and 2010, patients were contacted both by mail and telephone. In the case of nonresponse, the registration office, the health insurance, or the treating physician was contacted to retrieve information regarding the life status of the patient. In deceased patients, the cause of death was verified by death certificates and hospital records whenever possible using the International Classification of Diseases, 9th Revision.
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Control Population
The Cooperative Health Research in the Region of Augsburg (KORA) F3 survey 23 was performed in 2004 and represents a follow-up study of the population-based KORA S3 study. The S3 survey conducted in 1994/1995 was based on a random sampled of German residents of the Augsburg region aged 25 to 74 years identified through the public record office. For the purpose of the present study, 2835 normotensive and 2021 hypertensive subjects from the S3 survey were enrolled. Hypertension was defined as blood pressure Ն140/90 mm Hg and/or current use of antihypertensive drugs, given that the subjects were aware of being hypertensive.
More than 99.5% of the participants were white. 
Definitions
Diabetes mellitus was defined as a known history of diabetes mellitus at the time of first investigation of PA. Hypercholesterolemia was defined as total cholesterol Ͼ200 mg/dL and hypertriglyceridemia as total triglycerides Ͼ180 mg/dL. Overweight was defined as a BMI Ͼ25 kg/m 2 . Cardiovascular events were classified according to the International Classification of Diseases, 9th Revision.
Statistics
Results are expressed as meanϮ1 SD for normally distributed data and as median plus range in nonnormally distributed data, if not stated otherwise. A P value Ͻ0.05 was considered as significant. Matching between patients with PA and subjects from the KORA F3 survey was performed in a 1:2 fashion using age, sex, and BMI as matching variables, leading to a match in 300 patients and 600 normotensive and 600 hypertensive controls. Patients Ͻ30 years of age were excluded from the PA group for lack of counterparts in KORA. In addition, we matched for age, sex, and blood pressure using best-fit matching. Maximum matching variability for age was 5 years and for BMI 2 kg/m 2 . To increase the number of matches, a BMI mismatch of Ͼ2 kg/m 2 was accepted in Ͻ1% of cases. Significance of differences was analyzed by t test, Wilcoxon signedrank test with continuity correction, Fisher exact test, and McNemar 2 test with continuity correction, as appropriate. Kaplan-Meier plots were calculated to estimate the survival curves of PA patients and hypertensive controls (time of diagnosis to last contact or death in PA; date of survey to life status assessment/death in controls). Analyzing survival curves we used Cox regression and, if appropriate, also log-rank test. Cox regression was also used for regression analysis with multiple parameters to identify risk factors associated with death at the time of diagnosis. Potential risk factors were identified by manual backward elimination. Age, sex, BMI, systolic and diastolic blood pressure at first presentation, prevalent diabetes mellitus, lipid and potassium concentrations, plasma aldosterone and renin concentrations, and adrenalectomy were used for the initial model. All of the statistical analyses were carried out using R version 2.6.2 software.
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Results
Clinical Characteristics of the Study Populations
Clinical characteristics of the study populations are summarized in Table S1 , available in the online-only Data Supplement. As expected, the cohorts differed in multiple variables.
Mortality in the Case-Control Study
Using age, sex, and BMI as matching variables, a casecontrol study of 300 patients with PA and 600 normotensive and 600 hypertensive controls was performed (for clinical characteristics, see Table 1 ), and Kaplan-Meier survival plots were calculated. Controls had higher triglyceride and cholesterol concentrations (probably because of the nonfasting state), lower blood pressure levels, and less frequently diabetes mellitus. Plasma potassium, plasma aldosterone, and plasma renin levels were unavailable in the control cohort.
Despite clinical and metabolic differences, 5-and 10-year overall survival of patients with PA (96% and 90%, respectively) was similar to that of hypertensive controls (95% and 90%, log rank test, not significant) and not significantly different from normotensive control (98% and 95%, not significant; Figure 1 ). We also matched in a separate approach for systolic blood pressure (in addition to age and sex) to take blood pressure as one of the most important determinants of cardiovascular mortality into account. This decreased the number of matches to 288 (based on a 1:1 matching of patients with hypertensive controls) but did not change all-cause mortality, which remained comparable in the cohorts (Table S2 and Figure S1 ). Table 2 provides causes of death for PA patients and controls according to International Classification of Diseases, 9th Revision, classification. Cardiovascular causes were the main cause of death in the cohorts but were more frequent in PA than in controls (50% versus 34% in hypertensive controls [PϽ0.05%] versus 38% in normotensive controls). All-cause mortality, n (%) 22 (7) 74 (12) 47 (7) Coronary heart disease, n (%) 13 (4) Assuming that two thirds of the unknown causes of death are attributable to cardiovascular death, the differences to hypertensives and normotensives are highly significant (Pϭ0.004 and 0.02, respectively).
Causes and Risk Factors Associated With Mortality in PA
Hazard ratios (HRs) for variables likely associated with adverse outcome in PA were calculated. In univariate analysis, age, diabetes mellitus, and angina pectoris were associated with increased all-cause mortality ( Figure S2 ). This latter finding might be explained by a higher likelihood of aldosterone-producing adenoma and, consequently, adrenalectomy in severely hypokalemic PA patients (odds ratio, 1.9 [Fisher exact test] PϽ0.01).
Using age Ͼ50 years. diabetes mellitus. and angina pectoris as risk parameters, we developed a model with a scoring system of 0 to 3 points. As given in Figure 2 , patients with PA with a score of Ն2 had an increased mortality rate that becomes evident Ն6 years after diagnosis.
Discussion
Using data of the German Conn's Registry and a German control cohort of subjects from a population-based survey, we investigated long-term mortality of treated PA in Germany. By combining the data of 3 centers, we collected a total of 337 patients with confirmed PA. After matching for age, sex, BMI, or blood pressure, our data show that all-cause mortality in patients with PA is not significantly different from that of hypertensive controls. These data are in accordance with the hypothesis that treatment of PA by adrenalectomy or mineralocorticoid receptor antagonist medication reduces increased morbidity of untreated PA, 14 thereby reducing overall mortality. However, beyond 10 years of follow-up, mortality in PA patients appears to be higher than in hypertensive controls, but the number of patients is too low to reach statistical significance.
We matched the cohorts using confounders of mortality as matching variables, such as age, sex, BMI, or blood pressure. Nevertheless, the cohorts remained unbalanced for important variables, such as diabetes mellitus and plasma lipids (Tables  1 and S2 ). Patients with PA had initially a much higher diabetes mellitus prevalence than controls (14% versus 7%), a finding reported previously. 18 In contrast, control subjects had significantly higher total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels and lower highdensity lipoprotein levels, which might be at least in part explained by the nonfasting status of the KORA F3 subjects.
Numerous studies have shown that patients with PA have an increased risk for cardiovascular morbidity. In comparison with blood pressure-matched hypertensive controls without aldosterone excess, patients with PA have increased left ventricular mass and more severely impaired diastolic relaxation. 8, 25 This finding argues for aldosterone-specific effects on left ventricular function independent of blood pressure. Aldosterone excess results in glomerular hyperfiltration and microalbuminuria 26 and, after a prolonged period of time, in loss of glomerular function. 16 PA causes atherosclerotic changes in resistance arteries in fat biopsies. 11 Patients with PA have an increased risk of cerebrovascular events 10 and are more likely to experience atrial fibrillation and myocardial infarction. 10, 14 Patients with PA have increased left ventric- ular wall thicknesses and reduced diastolic function even in the absence of arterial hypertension, as shown by Stowasser et al 26 in familial hyperaldosteronism type 1. In summary, these data support the concept that aldosterone excess is detrimental not only through increased blood pressure and hypokalemia but also through blood pressure independent proinflammatory and profibrotic effects on the heart and vessel wall.
Longitudinal studies by Catena et al 14 and Sechi et al 27 have shown that unfavorable effects of aldosterone excess can be ameliorated by adrenalectomy and mineralocorticoid antagonist treatment, respectively. Microalbuminuria, although much more prevalent in PA, is reversed to a similar degree as in hypertensive controls treated conventionally with antihypertensive drugs. In addition, disease control by targeted treatment reduces the cardiovascular risk to a degree comparable to that of patients with primary hypertension. In this setting, magnetic resonance angiogram treatment seems to be similarly effective as adrenalectomy. Up to this point, no study had reported mortality data in PA. Our study shows that overall mortality after diagnosis of PA and initiation of specific treatment is similar to that of matched hypertensive controls. A detailed analysis of the causes of death indicates that 50% of all-cause mortality (and 69% of known mortality) is attributable to cardiovascular mortality. As summarized in Table 3 , a number of factors were associated with increased mortality in the presence of aldosterone excess. These include age, diabetes mellitus, and angina pectoris. It might be surprising that, in this context, a variable such as blood pressure is not associated with increased mortality. However, it is reasonable to assume that our study is underpowered to detect a significant effect of this variable. A separate analysis including all 4856 KORA F3 subjects shows that blood pressure is indeed a highly significant predictor (Pϭ0.003) of all-cause mortality (data not shown). Protective factors identified in our cohort were intervention by adrenalectomy and the presence of hypokalemia at diagnosis. The latter might be seen as an unexpected finding. Severe hypokalemia is an indirect measure of the level of aldosterone excess. Therefore, one might assume that severe hypokalemia can be detrimental in PA, increasing long-term mortality. However, 3 reasons may explain a favorable outcome with hypokalemia. First, the improved survival associated with severe hypokalemia may reflect earlier case detection of PA leading to more rapid treatment. Second, pronounced hypokalemia is frequently found in aldosterone-producing adenoma. Evidently more patients with severe hypokalemia had aldosterone-producing adenoma leading to a higher rate of adrenalectomy and possibly a better long-term control of blood pressure. Although the former is supported by the improved survival in PA patients undergoing adrenalectomy, the latter remains speculative because we cannot provide sufficient data of interim blood pressure measurements after adrenalectomy or spironolactone treatment. Third, an additional reason might be the more rapid therapeutic effect of adrenalectomy, which was shown for cardiac hypertrophy in PA patients.
14 Along the same line, 2 studies showed that preoperative potassium levels are predictors of blood pressure control after adrenalectomy. 28, 29 Based on age, diabetes mellitus, and angina pectoris, which remained significant in a multivariate model, we calculated a sum score associated with an adverse outcome. As shown in Figure 2 , patients with a score of Ն2 had an increased risk for death. The survival curves start to separate after 6 years of follow-up. These data suggest a lag period of several years until mortality increases in high-risk subjects, and long-term surveillance might be indicated accordingly. We believe that cardiovascular risk factors should be controlled tightly in patients who remain hypertensive after adrenalectomy or do not fully respond to mineralocorticoid antagonist therapy.
Limitations and Strengths of the Study
The strengths of our study are the large sample size of the PA cohort, the long period of follow-up, and the large hypertensive control cohort allowing a 2:1 matching. The limitations include the retrospective design of the analysis. For example, it is impossible to control for the intensity with which cardiovascular risk factors were managed in the PA subjects who were managed by hypertension specialists versus the matched subjects presumably managed by nonspecialists. Regression variables, such as blood pressure or diabetes mellitus, are entered into the model based on a single baseline measure but will have improved over time because of treatment effects. The magnitude of this effect could not be assessed in the present study. The control cohort was drawn from a population-based study and not from a patient cohort collected under similar conditions. Although subjects with PA were not excluded from our control cohort, we have reported previously that the prevalence of an elevated aldosterone:renin ratio in population-based cohorts is Ͻ5.1%.
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Furthermore, because of the high prevalence of essential hypertension, it is likely that, in a subgroup of our patients from our PA cohort, a component of essential hypertension was also present, indicating that a small overlap of diagnosis is virtually unavoidable in such an analysis.
In conclusion, our data show that all-cause mortality in patients with PA is similar to that of matched control hypertensives. PA patients at higher age and with coexisting conditions such as diabetes mellitus or angina pectoris are at higher risk and should be followed more closely in clinical practice.
Perspectives
PA is associated with increased cardiovascular and cerebrovascular morbidity in excess to what might be expected from elevated blood pressure. This has been attributed to additive direct effects of aldosterone on the endothelium and the myocardium. Our study provides for the first time long-term data on mortality in PA. Mortality rates of treated patients with PA proved to be not different from those of matched hypertensives. Depending on the perspective, one might see the glass half-full (at least similar mortality rate to matched hypertensives) or half empty (a lower mortality rate might have been expected because of the often well-controlled blood pressure levels after initiation of specific treatment for PA). In the future, earlier detection of PA and more intensive blood pressure management after diagnosis hold the promise of a better outcome than shown in our study. 
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Summary
PA patients at higher age and with coexisting conditions, such as diabetes mellitus or angina pectoris, are at higher risk and should be followed more closely in clinical practice. Table S1 : Baseline characteristics of patients with PA and hypertensive/normotensive controls. P-value for test against PA patients. Shown is the median plus range or the mean±standard deviation (blood pressure). Normal ranges: plasma renin activity 0.8-4.0 ng/ml/h; plasma renin concentration: 8-99 µU/ml; plasma aldosterone concentration: 40-160 pg/ml. Ns = not significant. * Nonfasting.
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